Tianjie Liu

Tianjie Liu

Auto-generated profile, based on publicly available information

Tianjie Liu

Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cancer Letters
Verified
Journal Article
Open access
YZYujiao Zhang
Yujiao Zhang
YFYizeng Fan
Yizeng Fan
XJXin Jing
Xin Jing
LZLin Zhao
Lin Zhao
TLTianjie Liu
Tianjie Liu
YTYan Teng
Yan Teng
Macrophages, which are highly plastic, can be polarized to M1 or M2 subtypes according to the diverse signals in complex microenvironment. Studies have shown the activation of YAP, an oncogenic transcriptional co-activator, increased macrophage recruitment. However, its role in macrophage polarization remains to be elucidated, especially in triple-negative breast cancer (TNBC) progression. Here we found TNBC cells increased YAP expression in macrophages, which depended on OTUD5-mediated deubiquitination and stabilization of YAP, then the high expression of YAP polarized macrophage to the M2-like phenotype. Moreover, the elevation of YAP in M2-like macrophage promotes the pro-metastatic potential of TNBC cells via MCP-1/CCR2 pathway. We also observed high expression of YAP in M2 macrophage was negatively related to survival. Collectively, our finding suggested the therapeutic strategy that targets YAP+ M2 macrophage could be a novel option for TNBC treatment.

3 March 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
YFYizeng Fan
Yizeng Fan
YWYuzhao Wang
Yuzhao Wang
WDWeichao Dan
Weichao Dan
YZYilei Zhang
Yilei Zhang
LNLi Nie
Li Nie
LLLei Li
Lei Li

1 February 2021 in Cancer Letters
Verified
Journal Article
Closed access
JBJi-Yu Bai
Ji-Yu Bai
BJBen Jin
Ben Jin
JMJian-Bin Ma
Jian-Bin Ma
TLTian-Jie Liu
Tian-Jie Liu
CYChao Yang
Chao Yang
PGPeng Guo
Peng Guo

22 January 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YGYanan Gu
Yanan Gu
SWShiqi Wu
Shiqi Wu
JFJunjie Fan
Junjie Fan
ZMZeji Meng
Zeji Meng
GGGuoqiang Gao
Guoqiang Gao
KWKaijie Wu
Kaijie Wu
Prostate cancer (PCa) is one of the most common malignancy in men. However, the molecular mechanism of its pathogenesis has not yet been elucidated. In this study, we demonstrated that CYLD, a novel deubiquitinating enzyme, impeded PCa development and progression via tumor suppression. First, we found that CYLD was downregulated in PCa tissues, and its expression was inversely correlated with pathological grade and clinical stage. Moreover, we discovered that CYLD inhibited tumor cell proliferation and enhanced the sensitivity to cell ferroptosis in PCa in vitro and in vivo, respectively. Mechanistically, we demonstrated that CYLD suppressed the ubiquitination of YAP protein, then promoted ACSL4 and TFRC mRNA transcription. Then, we demonstrated that CYLD could enhance the sensitivity of PCa xenografts to ferroptosis in vivo. Furthermore, we discovered for the first time that there was a positive correlation between CYLD expression and ACSL4 or TFRC expression in human PCa specimens. The results of this study suggested that CYLD acted as a tumor suppressor gene in PCa and promoted cell ferroptosis through Hippo/YAP signaling.

29 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJian Ma
Jian Ma
LLLei Li
Lei Li
BMBohan Ma
Bohan Ma
TLTianjie Liu
Tianjie Liu
ZWZixi Wang
Zixi Wang
WWWenyi Wei
Wenyi Wei
CDK4/6 inhibitors (CDK4/6i) show anticancer activity in certain human malignancies, such as breast cancer. However, their application to other tumor types and intrinsic resistance mechanisms are still unclear. Here, we demonstrate that MYC amplification confers resistance to CDK4/6i in bladder, prostate and breast cancer cells. Mechanistically, MYC binds to the promoter of the E3 ubiquitin ligase KLHL42 and enhances its transcription, leading to RB1 deficiency by inducing both phosphorylated and total pRB1 ubiquitination and degradation. We identify a compound that degrades MYC, A80.2HCl, which induces MYC degradation at nanomolar concentrations, restores pRB1 protein levels and re-establish sensitivity of MYC high-expressing cancer cells to CDK4/6i. The combination of CDK4/6i and A80.2HCl result in marked regression in tumor growth in vivo. Altogether, these results reveal the molecular mechanisms underlying MYC-induced resistance to CDK4/6i and suggest the utilization of the MYC degrading molecule A80.2HCl to potentiate the therapeutic efficacy of CDK4/6i.

9 September 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
THTao Hou
Tao Hou
WDWeichao Dan
Weichao Dan
TLTianjie Liu
Tianjie Liu
BLBo Liu
Bo Liu
YWYi Wei
Yi Wei
LLLei Li
Lei Li
The mechanistic (formally “mammalian”) target of rapamycin (mTOR) pathway serves as a crucial regulator of various biological processes such as cell growth and cancer progression. In bladder cancer, recent discoveries showing the cancer-promoting role of mTOR complex 1 have attracted wide attention. However, the regulation of mTOR signaling in bladder cancer is complicated and the underlying mechanism remains elusive. Here, we report that the deubiquitinating enzyme, ovarian tumor domain-containing protein 5 (OTUD5), can activate the mTOR signaling pathway, promote cancer progression, and show its oncogenic potential in bladder cancer. In our study, we found that OTUD5 deubiquitinated a RING-type E3 ligase, RNF186, and stabilized its function. In addition, the stabilization of RNF186 further led to the degradation of sestrin2, which is an inhibitor of the mTOR signaling pathway. Together, we provide novel insights into the pathogenesis of bladder cancer and first prove that OTUD5 can promote bladder cancer progression through the OTUD5-RNF186-sestrin2-mTOR axis, which may be exploited in the future for the diagnosis and treatment of this malignancy.